{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:27:13Z","timestamp":1776310033770,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T00:00:00Z","timestamp":1392595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Nonsteroidal anti-inflammatory drugs (NSAIDs) 1\u20135 containing an N-acyl hydrazone subunit were prepared and their antiplatelet and antithrombotic activities assessed in vitro and in vivo. Compounds 1\u20135 inhibited the platelet aggregation induced by adenosine diphosphate and\/or arachidonic acid, with inhibition rates of 18.0%\u201361.1% and 65.9%\u201387.3%, respectively. Compounds 1 and 5 were the most active compounds, inhibiting adenosine-diphosphate-induced platelet aggregation by 57.2% and 61.1%, respectively. The inhibitory rates for arachidonic-acid-induced platelet aggregation were similar for compound 2 (80.8%) and acetylsalicylic acid (ASA, 80%). After their oral administration to mice, compounds 1, 3, and 5 showed shorter mean bleeding times than ASA. Compounds 1 and 5 also protected against thromboembolic events, with survival rates of 40% and 33%, respectively, compared with 30% for ASA. In conclusion, these results indicate that these novel NSAIDs containing an NAH subunit may offer better antiplatelet and antithrombotic activities than ASA.<\/jats:p>","DOI":"10.3390\/molecules19022089","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T13:44:35Z","timestamp":1392644675000},"page":"2089-2099","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Antiplatelet and Antithrombotic Activities of Non-Steroidal Anti-Inflammatory Drugs Containing an N-Acyl Hydrazone Subunit"],"prefix":"10.3390","volume":"19","author":[{"given":"Rafael","family":"Chelucci","sequence":"first","affiliation":[{"name":"Departamento de F\u00e1rmacos e Medicamentos, Faculdade de Ci\u00eancias Farmac\u00eauticas\u2013UNESP, Rodovia Araraquara Ja\u00fa Km, Araraquara, SP, 01, 14801-902, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz","family":"Dutra","sequence":"additional","affiliation":[{"name":"Departamento de F\u00e1rmacos e Medicamentos, Faculdade de Ci\u00eancias Farmac\u00eauticas\u2013UNESP, Rodovia Araraquara Ja\u00fa Km, Araraquara, SP, 01, 14801-902, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lopes Pires","sequence":"additional","affiliation":[{"name":"Departamento de F\u00e1rmacos e Medicamentos, Faculdade de Ci\u00eancias Farmac\u00eauticas\u2013UNESP, Rodovia Araraquara Ja\u00fa Km, Araraquara, SP, 01, 14801-902, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais","family":"De Melo","sequence":"additional","affiliation":[{"name":"Departamento de F\u00e1rmacos e Medicamentos, Faculdade de Ci\u00eancias Farmac\u00eauticas\u2013UNESP, Rodovia Araraquara Ja\u00fa Km, Araraquara, SP, 01, 14801-902, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila","family":"Bosquesi","sequence":"additional","affiliation":[{"name":"Departamento de F\u00e1rmacos e Medicamentos, Faculdade de Ci\u00eancias Farmac\u00eauticas\u2013UNESP, Rodovia Araraquara Ja\u00fa Km, Araraquara, SP, 01, 14801-902, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Chung","sequence":"additional","affiliation":[{"name":"Departamento de F\u00e1rmacos e Medicamentos, Faculdade de Ci\u00eancias Farmac\u00eauticas\u2013UNESP, Rodovia Araraquara Ja\u00fa Km, Araraquara, SP, 01, 14801-902, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Dos Santos","sequence":"additional","affiliation":[{"name":"Departamento de F\u00e1rmacos e Medicamentos, Faculdade de Ci\u00eancias Farmac\u00eauticas\u2013UNESP, Rodovia Araraquara Ja\u00fa Km, Araraquara, SP, 01, 14801-902, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2014,2,17]]},"reference":[{"key":"ref_1","first-page":"e6","article-title":"Heart disease and stroke statistics\u20142013 update: A report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mahmood, S.S., Levy, D., Vasan, R.S., and Wang, T.J. (2013). The framingham heart study and the epidemiology of cardiovascular disease: A historical perspective. Lancet.","DOI":"10.1016\/S0140-6736(13)61752-3"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","article-title":"A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques","volume":"55","author":"Reininger","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1570161043476456","article-title":"Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents","volume":"2","author":"Goto","year":"2004","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.292.15.1867","article-title":"Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease","volume":"292","author":"Tran","year":"2004","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: Cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. Invest."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40261-013-0052-6","article-title":"Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: Implications for clinical practice","volume":"33","author":"Barbosa","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: Cumulativemeta-analysis","volume":"364","author":"Juni","year":"2004","journal-title":"Lancet"},{"key":"ref_10","first-page":"347","article-title":"Cardiovascular complications of non-steroidal anti-inflammatory drugs","volume":"35","author":"Fosslien","year":"2005","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"JAMA"},{"key":"ref_12","first-page":"S19","article-title":"Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis","volume":"92","author":"Turajane","year":"2009","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/03009749109096948","article-title":"Long-term safety of ketoprofen in an elderly population of arthritic patients","volume":"91","author":"Schattenkirchner","year":"1991","journal-title":"Scand. J. Rheumatol. Suppl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.108.805689","article-title":"Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease","volume":"2","author":"Ray","year":"2009","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.0000258106.74139.25","article-title":"Cardiovascular effects of the cyclooxygenase inhibitors","volume":"49","author":"White","year":"2007","journal-title":"Hypertension"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2007.03.032","article-title":"Synthesis and anti-platelet activity of novel arylsulfonate--acylhydrazone derivatives, designed as antithrombotic candidates","volume":"43","author":"Lima","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1113\/jphysiol.1963.sp007185","article-title":"The aggregation of blood platelets","volume":"168","author":"Born","year":"1963","journal-title":"J. Physiol. (Lond.)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/12081910","article-title":"Biological activities of hydrazone derivatives","volume":"12","author":"Rollas","year":"2007","journal-title":"Molecules"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1590\/S0100-40421999000500019","article-title":"S\u00edntese de subst\u00e2ncias bioativas na cascata do \u00e1cido araquid\u00f4nico: Antiinflamat\u00f3rios, analg\u00e9sicos e antitromb\u00f3ticos (in Portuguese)","volume":"22","author":"Barreiro","year":"1999","journal-title":"Quim. Nova"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1016\/j.bmc.2005.03.003","article-title":"Synthesis and vasodilatory activity of new N-acilhidrazones derivatives designed as LASSBio-294 analogues","volume":"13","author":"Silva","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(03)01757-6","article-title":"Thienylhydrazone derivative increase sarcoplasmic reticulum Ca+ releasein mammalian skeletal muscle","volume":"470","author":"Sudo","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0928-0987(00)00102-0","article-title":"Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists","volume":"11","author":"Fraga","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0223-5234(98)80008-1","article-title":"Synthesis of new 2-pyridinylarylhydrazones and evaluation of their analgesic, anti-inflammatory and antiplatelet profile","volume":"33","author":"Todeschini","year":"1998","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1248\/cpb.c12-00597","article-title":"Synthesis of novel indole hydrazone derivatives and evaluation of their antiplatelet aggregation activity","volume":"61","author":"Mashayekhi","year":"2013","journal-title":"Chem. Pharm. Bull."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejphar.2010.04.003","article-title":"Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition","volume":"638","author":"Brito","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0968-0896(03)00055-5","article-title":"Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives","volume":"11","author":"Cunha","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1248\/cpb.c12-00651","article-title":"One pot synthesis and biological activity evaluation of novel Schiff bases derived from 2-hydrazinyl-1,3,4-thiadiazole","volume":"61","author":"Tehrani","year":"2013","journal-title":"Chem. Pharm. Bull."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1538-7836.2007.02356.x","article-title":"Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin","volume":"5","author":"Cattaneo","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1074248410381758","article-title":"Antiplatelet therapy in acute coronary syndromes","volume":"16","author":"Aragam","year":"2011","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ane.12111","article-title":"Clinical consequences of aspirin and clopidogrel resistance: An overview","volume":"128","author":"Mijajlovic","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.amjcard.2013.04.055","article-title":"Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes","volume":"112","author":"Berger","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0210-5705(12)70032-8","article-title":"Gastrointestinal bleeding associated with NSAIDs, antiplatelet therapy and anticoagulant agent","volume":"35","author":"Lanas","year":"2012","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2013.09.032","article-title":"Drug\/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets","volume":"721","author":"Saxena","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.nut.2011.11.032","article-title":"Antithrombotic activity of argan oil: An in vivo experimental study","volume":"28","author":"Mekhfi","year":"2012","journal-title":"Nutrition"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-3565(25)33551-2","article-title":"Mouse antithrombotic assays: A simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol","volume":"227","author":"DiMinno","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","unstructured":"Dutra, L.A., Chelucci, R.C., Chiquetto, R., Pires, M.E.L., Marcondes, S., Chung, M.C., and Santos, J.L. (2012, January 28\u201331). Synthesis of new NSAIDs derivatives designed as antiplatelet, analgesic and anti-inflammatory compounds. Proceedings of the 6th Brazilian Symposium on Medicinal Chemistry, Canela, Rio Grande ds Sul, Brazil. OSPS-45."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0049-3848(79)90064-1","article-title":"Bleeding time in laboratory animals. II\u2014A comparison of different assay conditions in rats","volume":"15","author":"Dejana","year":"1979","journal-title":"Thromb. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0049-3848(79)90065-3","article-title":"Bleeding time in laboratory animals. III\u2014Do tail bleeding times in rats only measure a platelet defect? (the aspirin puzzle)","volume":"15","author":"Dejana","year":"1979","journal-title":"Thromb. Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/19\/2\/2089\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:08:13Z","timestamp":1760216893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/19\/2\/2089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,17]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2]]}},"alternative-id":["molecules19022089"],"URL":"https:\/\/doi.org\/10.3390\/molecules19022089","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,17]]}}}